{
    "nct_id": "NCT05558696",
    "official_title": "A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV)",
    "inclusion_criteria": "* Has a diagnosis of Polycythemia Vera per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms\n* Has a bone marrow fibrosis score of Grade 0 or Grade 1\n* Has failed at least one standard cytoreductive therapy to lower hematocrit\n* Has a life expectancy >36 weeks\n* Has discontinued prior cytoreductive therapy for 2 weeks (4 weeks for interferon) prior to study drug initiation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or greater\n* Has unresolved treatment related toxicities from prior therapies (unless resolved to â‰¤ Grade 1)\n* Has an uncontrolled active infection\n* Has a known human immunodeficiency virus (HIV) infection or active Hepatitis B or Hepatitis C virus infection\n* Has evidence of increased risk of bleeding, including known bleeding disorders\n* Is pregnant or lactating",
    "miscellaneous_criteria": ""
}